Sugi Predict

Sugi Predict / Compounds / SCHEMBL652083

SCHEMBL652083

SCHEMBL652083

COc1ccccc1/N=C1/NC(=O)/C(=C/c2cnc(NC(=O)CCC(=O)O)s2)S1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.52
▸ MEN1 O00255 4/20 0.52
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ HSD11B1 P28845 1/20 0.46
▸ PTP4A3 O75365 1/20 0.45
▸ MAP4K4 O95819 3/20 0.43
▸ PIM1 P11309 3/20 0.43
▸ DYRK1A Q13627 3/20 0.43
▸ PIM3 Q86V86 3/20 0.43
▸ MKNK2 Q9HBH9 3/20 0.43
▸ CDC7 O00311 2/20 0.43
▸ PLK4 O00444 2/20 0.43
▸ DAPK3 O43293 2/20 0.43
▸ DYRK3 O43781 2/20 0.43
▸ PRKD3 O94806 2/20 0.43
▸ CDK1 P06493 2/20 0.43
▸ LYN P07948 2/20 0.43
▸ PHKG2 P15735 2/20 0.43
▸ RPS6KB1 P23443 2/20 0.43
▸ CSNK1A1 P48729 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL652084 1.00 KMT2A (0.52) KMT2AMEN1L3MBTL1HSD11B1PTP4A3
SCHEMBL653323 0.89 HSD11B1 (0.42) KMT2AMEN1L3MBTL1HSD11B1PTP4A3
SCHEMBL653324 0.89 HSD11B1 (0.42) KMT2AMEN1L3MBTL1HSD11B1PTP4A3
SCHEMBL651553 0.88 MEN1 (0.55) KMT2AMEN1L3MBTL1HSD11B1PTP4A3
SCHEMBL651554 0.88 MEN1 (0.55) KMT2AMEN1L3MBTL1HSD11B1PTP4A3
SCHEMBL653261 0.86 NPC1 (0.50) KMT2AMEN1MAP4K4PIM1DYRK1A
SCHEMBL653260 0.86 NPC1 (0.50) KMT2AMEN1MAP4K4PIM1DYRK1A
SCHEMBL649011 0.86 MET (0.44) KMT2AMEN1L3MBTL1HSD11B1DYRK3
SCHEMBL649012 0.86 MET (0.44) KMT2AMEN1L3MBTL1HSD11B1DYRK3
SCHEMBL10226351 0.86 MET (0.44) KMT2AMEN1L3MBTL1HSD11B1DYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 — — EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 — — US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 — — US disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 — — US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 — — US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 — — US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 — — US disclosed
WO-2010122979-A1 THIAZOLIDINONE DERIVATIVE ＳＢＩバイオテック株式会社 (JP) 2010-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 KMT2A 3437/4885MEN1 1406/4885L3MBTL1 2190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.